3M to pay $7.35B to settle PFAS injury claims for up to 120,000 plaintiffs

Settlement details and financial impact

3M has agreed to a $7.35 billion settlement over nine years to resolve personal injury claims related to exposure to PFAS, or 'forever chemicals,' according to reports from Mint. The settlement covers approximately 99% of the current personal injury claims against the company, involving between 115,000 and 120,000 plaintiffs.

The company will record a $5.8 billion pre-tax charge in the fourth quarter of 2026 but has stated that this will not affect its previously issued financial forecast. Payments will begin in 2026 with an initial $50 million, followed by a gap in 2027. About 20% of the total payments aredue during the final two years of the agreement.

3M’s stance and broader context

3M has not admitted liability in the settlement and stated it remains prepared to defend itself in ongoing or future litigation. This settlement follows a $10.3 billion agreement in 2023 to resolve claims related to PFAS contamination in public water systems.

PFAS, a group of manufactured chemicals, are widely used in products designed to resist heat, stains, grease, and water. Exposure to certain PFAS has been linked to health issues, including liver damage, lower birth weight, reduced vaccine efficacy, and cancers of the kidney and testes.

Competitors and industry implications

The settlement highlights the growing legal and financial risks faced by companies involved in chemical manufacturing, particularly those producing PFAS. Competitors such as DuPont, Corteva, and Chemours have also faced litigation related to PFAS exposure, signaling a broader industry challenge.

3M has completed its exit from global PFAS manufacturing by the end of 2025, a move that may influence how other companies in the sector address regulatory and legal pressures.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

For founders and operators in industries adjacent to chemical manufacturing or public health, 3M’s settlement underscores the mounting financial and reputational risks of legacy products like PFAS. The scale of the payout—covering nearly all current claims—suggests that regulatory and legal scrutiny of 'forever chemicals' is far from over. Companies still producing or using PFAS may face similar litigation, particularly as public awareness of health risks grows.

The settlement also serves as a cautionary tale for conglomerates with diverse product portfolios. Even if a product line contributes minimally to revenue, its legal liabilities can disproportionately impact the balance sheet. 3M’s decision to exit PFAS manufacturing entirely reflects a strategic pivot to mitigate long-term risk, a playbook that other firms might emulate.

Related on Lazyfounder

• More business news